David R. Shalinsky

5.4k total citations · 4 hit papers
52 papers, 4.3k citations indexed

About

David R. Shalinsky is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, David R. Shalinsky has authored 52 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 20 papers in Oncology and 16 papers in Cancer Research. Recurrent topics in David R. Shalinsky's work include Angiogenesis and VEGF in Cancer (16 papers), Protease and Inhibitor Mechanisms (9 papers) and Cancer, Hypoxia, and Metabolism (5 papers). David R. Shalinsky is often cited by papers focused on Angiogenesis and VEGF in Cancer (16 papers), Protease and Inhibitor Mechanisms (9 papers) and Cancer, Hypoxia, and Metabolism (5 papers). David R. Shalinsky collaborates with scholars based in United States, Italy and Canada. David R. Shalinsky's co-authors include Dana D. Hu‐Lowe, Donald M. McDonald, Tetsuichiro Inai, Michael R. Mancuso, Helen Y. Zou, Tsutomu Nakahara, Scott M. Norberg, Krzysztof Appelt, Fabienne Baffert and Peter Bałuk and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

David R. Shalinsky

52 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

2006 641 citations Michael R. Mancuso, Rachel Davis et al. Journal of Clinical Investigation profile →
Inhibition of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane Ghosts

2004 589 citations Tetsuichiro Inai, Michael R. Mancuso et al. profile →
Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

2008 515 citations Dana D. Hu‐Lowe, Helen Y. Zou et al. Clinical Cancer Research profile →
Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

2008 494 citations Ezra E.W. Cohen, Lee S. Rosen et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by David R. Shalinsky

Since Specialization

Citations

This map shows the geographic impact of David R. Shalinsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David R. Shalinsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David R. Shalinsky more than expected).

Fields of papers citing papers by David R. Shalinsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David R. Shalinsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David R. Shalinsky. The network helps show where David R. Shalinsky may publish in the future.

Co-authorship network of co-authors of David R. Shalinsky

This figure shows the co-authorship network connecting the top 25 collaborators of David R. Shalinsky. A scholar is included among the top collaborators of David R. Shalinsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David R. Shalinsky. David R. Shalinsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors 2016 ·Cancer Chemotherapy and Pharmacology ·Justine Y. Bruce, Patricia LoRusso, Priscila Gonçalves, Elisabeth I. Heath, Elizabeth A. Sadowski, David R. Shalinsky, Yanwei Zhang, Anne M. Traynor, Aurora Breazna, Alejandro D. Ricart, Michael A. Tortorici, Glenn Liu	3
2	Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma 2011 ·Clinical Cancer Research ·John P. Fruehauf, Jose Lutzky, David H. McDermott, Charles K. Brown, Jean‐Baptiste Méric, Brad Rosbrook, David R. Shalinsky, Katherine Liau, Andreas G. Niethammer, Sinil Kim, Olivier Rixe	93
3	Novel Ultrasound and DCE-MRI Analyses After Antiangiogenic Treatment With a Selective VEGF Receptor Inhibitor 2011 ·Ultrasound in Medicine & Biology ·Katherine D. Watson, Xiaowen Hu, Chun-Yen Lai, Heather A. Lindfors, Dana D. Hu‐Lowe, Theresa Tuthill, David R. Shalinsky, Katherine W. Ferrara	7
4	Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study breakdown → 2008 ·Journal of Clinical Oncology ·Ezra E.W. Cohen, Lee S. Rosen, Everett E. Vokes, Merrill S. Kies, Arlene A. Forastiere, Francis P. Worden, Madeleine Kane, Eric J. Sherman, Sinil Kim, Paul Bycott, Michael A. Tortorici, David R. Shalinsky, Katherine Liau, Roger B. Cohen	494
5	Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 breakdown → 2008 ·Clinical Cancer Research ·Dana D. Hu‐Lowe, Helen Y. Zou, Maren L. Grazzini, Max Hallin, Grant Wickman, Karin Amundson, Jeffrey H. Chen, David A. Rewolinski, Shinji Yamazaki, Xinglin Wu, Michele McTigue, Brion W. Murray, Robert S. Kania, Patrick M. O’Connor, David R. Shalinsky, Steve Bender	515
6	AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging 2007 ·Magnetic Resonance Imaging ·Lisa J. Wilmes, Maria G. Pallavicini, L. Fleming, Jessica Gibbs, Donghui Wang, (unknown), Savannah C. Partridge, Roland G. Henry, David R. Shalinsky, Dana D. Hu‐Lowe, John W. Park, Teresa M. McShane, Ying Lü, Robert C. Brasch, Nola M. Hylton	124
7	Phase I trial of SU014813 in patients (pts) with advanced solid malignancies 2007 ·Journal of Clinical Oncology ·Walter Fiedler, Giuseppe Giaccone, Peter Lasch, (unknown), Nicoletta Brega, Susan Raber, David R. Shalinsky, (unknown), Carsten Bokemeyer, E. Boven	2
8	Positron-emission tomography reveals early flare in uptake of FLT in tumors following chemotherapy with gemcitabine 2007 ·Journal of Clinical Oncology ·Grant A. McArthur, R M Hicks, David R. Shalinsky, (unknown), Cecilia O’Kane, Annette Hogg, Richard Fisher, Timothy J. McCarthy, Kenna Anderes	3
9	Rapid vascular regrowth in tumors after reversal of VEGF inhibition breakdown → 2006 ·Journal of Clinical Investigation ·Michael R. Mancuso, Rachel Davis, Scott M. Norberg, Shaun O’Brien, Barbara Sennino, Tsutomu Nakahara, Virginia Yao, Tetsuichiro Inai, Peter C. Brooks, Bruce Freimark, David R. Shalinsky, Dana D. Hu‐Lowe, Donald M. McDonald	641
10	Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor‐receptor tyrosine kinase inhibitor: Assessment by voxel analysis of dynamic contrast‐enhanced MRI 2005 ·Journal of Magnetic Resonance Imaging ·Ka‐Loh Li, Lisa J. Wilmes, Roland G. Henry, Maria G. Pallavicini, John W. Park, Dana D. Hu‐Lowe, Teresa M. McShane, David R. Shalinsky, (unknown), Robert C. Brasch, Nola M. Hylton	53
11	AG-028262, a novel selective VEGFR tyrosine kinase antagonist that potently inhibits KDR signaling and angiogenesis in vitro and in vivo 2004 ·Cancer Research ·Helen Y. Zou, Qiuhua Li, Maren L. Grazzini, (unknown), Karin Amundson, (unknown), Grant Wickman, (unknown), (unknown), Scott Jacobs, (unknown), Brion W. Murray, Michele McTigue, (unknown), Jihong Lou, David C. Gale, Steve Bender, Robert S. Kania, David R. Shalinsky, Dana D. Hu‐Lowe	7
12	Ventilator-Induced Lung Injury Upregulates and Activates Gelatinases and EMMPRIN 2001 ·American Journal of Respiratory Cell and Molecular Biology ·Hussein D. Foda, Ellen E. Rollo, Michelle Drews, Cathleen Conner, Krzysztof Appelt, David R. Shalinsky, Stanley Zucker	115
13	Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials 1999 ·Annals of the New York Academy of Sciences ·David R. Shalinsky, (unknown), Helen Y. Zou, Colleen D. McDermott, Peter Forsyth, Dylan R. Edwards, Stephen A. Margosiak, Sabine Bender, Gary A. Truitt, Alexander W. Wood, Nissi Varki, Krzysztof Appelt	202
14	Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations 1998 ·Investigational New Drugs ·David R. Shalinsky, (unknown), Helen Y. Zou, (unknown), Alexander W. Wood, Stephanie Webber, Krzysztof Appelt	26
15	The efficacy of 9-cis retinoic acid in experimental models of cancer 1996 ·Breast Cancer Research and Treatment ·Marco M. Gottardis, William W. Lamph, David R. Shalinsky, Anton Wellstein, R A Heyman	61
16	Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin. 1993 ·Journal of Clinical Oncology ·(unknown), Edward F. McClay, Steven C. Plaxe, S. S. C. YEN, (unknown), S Kirmani, (unknown), Dennis D. Heath, David R. Shalinsky, James L. Freddo	31
17	Modulation of cisplatin cytotoxicity by permeabilization of the plasma membrane by digitonin in vitro 1993 ·Biochemical Pharmacology ·Antti Jekunen, David R. Shalinsky, Doreen K. Hom, (unknown), Dennis D. Heath, Stephen B. Howell	31
18	Regional lymphatic drug exposure following intraperitoneal administration of 5-fluorouracil, carboplatin, and etoposide 1993 ·Surgical Oncology ·Per Lindnér, Dennis D. Heath, David R. Shalinsky, Stephen B. Howell, Peter Naredi, L Hafström	12
19	In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. 1993 ·Journal of Clinical Investigation ·R D Christen, Antti Jekunen, Jeffrey A. Jones, F Thiébaut, David R. Shalinsky, Stephen B. Howell	51
20	Inhibition of GSH-dependent PGH2 isomerase in mammary adenocarcinoma cells by allicin. 1989 ·Prostaglandins ·David R. Shalinsky, Dennis B. McNamara, K. C. AGRAWAL	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact